Delaying the use of high-dose melphalan with stem cell rescue in multiple myeloma is ready for prime time.
This article discusses the historic context of HDM-ASCT, the modern role of HDM-ASCT given the availability of highly sensitive MRD testing, and the likely future of quadruplet treatment. In summary, patients who attain deep responses using IMiD- and PI-based regimens may not require early HDM-ASCT. A delayed approach to this treatment is acceptable, and might be preferred by patients.
PMID: 31730582 [PubMed - in process]
Source: Clinical Advances in Hematology and Oncology - Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Food and Drug Administration (FDA) | Hematology | Myeloma | Stem Cell Therapy | Stem Cells | Toxicology | Transplants